Nasus Pharma NSRX
NYSE NSRX
$2.90 -0.08 (-2.61%)
As of: Nov 11, 2026 · 9:32 AM EST

Nasus Pharma (NSRX) Accumulated Expenses (2024 - 2025)

Updated

Nasus Pharma (NSRX) posted Accumulated Expenses of $553,000 for Q4 2025, down 34.5% from $844,000 a year earlier.

Analysis

Nasus Pharma (NSRX) Accumulated Expenses (2024 - 2025) Analysis & Trends

  • In prior years, Nasus Pharma's Accumulated Expenses was $844,000 in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Nasus Pharma 26.87 Mn 10.15 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 553,000.00
Dec 31, 2024 844,000.00
API Access

Nasus Pharma Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=NSRX&period=max&api_key=YOUR_API_KEY